Available Until 10/18/2022

Pharmacotherapy Specialty Recertification Literature Study: Module 1A-C (Cert # L229101)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 03/16/2022
Content Release Date: 04/13/2022
Expiration Dates: 10/18/2022
Activity Type: Application-based
CE Credits: 15 contact hours
Activity Fee: $55 (ASHP member); $110 (non-member)

Activity Overview

The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 3 online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice and includes a short video for enhanced learning and understanding. 

Module 1AMedication Safety and Statistics: This module focuses on medication safety issues and research evaluation. 

Module 1BInfectious Diseases: This module focuses on current issues in infectious diseases including updated guidelines, reviews, and clinical trials. 

Module 1CPediatrics, Pain, and Neurology: This module focuses on pediatrics, pain management, and the treatment and prevention of ischemic stroke. 

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.

 

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

These Literature Studies are designed to help board-certified pharmacists who are seeking recertification contact hours through the Board of Pharmacy Specialties (BPS).

Board certified pharmacists are eligible to receive up to 15 contact hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity

ACPE Number

Contact Hours (ACPE and BPS)

Assessment Pass Point

Pharmacotherapy and Critical Care Literature Study Module 1A: Medication Safety and Statistics

0204-0000-22-932-H01-P

5.0

72%

Pharmacotherapy Literature Study Module 1B: Infectious Diseases

0204-0000-22-939-H01-P

5.0

72%

Pharmacotherapy Literature Study Module 1C: Pediatrics, Pain, and Neurology

0204-0000-22-934-H01-P

5.0

79%

Module 1A: Medication Safety and Statistics
0204-0000-22-932-H01-P

This module focuses on medication safety issues and research evaluation.   

Owen VS, Rosgen BK, Cherak SJ et al. Adverse events associated with administration of vasopressor medications through a peripheral intravenous catheter: a systematic review and meta-analysis. Crit Care. 2021: 25:146.

Learning Objectives:

  • Describe the systematic review and meta-analysis by Owen and colleagues of studies of the administration of vasopressor medications through a peripheral intravenous (PIV) catheter.
  • Develop recommendations for the route of administration of vasopressor medications.

Nazer LH, Brown ART, Awad W. Iatrogenic toxicities in the intensive care unit. Critical Care Clinics. 2021; 37 (3): 625 - 641.

Learning Objectives:

  • Describe the mechanisms, clinical presentation, diagnosis, and management of iatrogenic toxicities associated with medications commonly used in the intensive care unit (ICU).
  • Develop recommendations for the management of iatrogenic toxicities associated with medications commonly used in the intensive care unit (ICU).

Kane-Gill SL. Nephrotoxin stewardship. Critical Care Clinics 2021; 37: 303-320.

Learning Objectives:

  • Define nephrotoxin stewardship and describe its goals and the approaches used to achieve them.
  • Develop recommendations for nephrotoxin stewardship to improve medication safety, ensure kidney health, and minimize unnecessary costs for medical tests and treatments for critically-ill patients.

Kollef MH, Torres A, Shorr AF et al. Nosocomial infection. Crit Care Med. 2021: 49: 169-187.

Learning Objectives:

  • Describe trends in nosocomial infections (NIs) in the intensive care unit (ICU) setting, the roles of the host-microbiome interaction and antimicrobial resistance, and strategies for the treatment and prevention of these infections.
  • Develop recommendations for the management of nosocomial infections (NIs) in patients in the intensive care unit (ICU).

Afanasjeva J, Burk M, Cunningham FF, et al. ASHP Guidelines on Medication-Use Evaluation. Am J Health Syst Pharm. 2021; 78(2): 168-175. https://pubmed.ncbi.nlm.nih.gov/33399190/.

Learning Objectives:

  • Describe the 2021 ASHP guidelines on medication-use evaluation (MUE), including goals and objectives, performance improvement methods, indicators suggesting a need for MUE, prioritization of medications and processes for evaluation, typical steps in the process, roles and responsibilities of the interdisciplinary team, and common problems and pitfalls.
  • Develop recommendations for medication-use evaluations (MUEs), including goals, methods, roles and responsibilities of team members, indicators of the need for MUE, and common pitfalls.

Gershon AS, et al. Informing healthcare decisions with observational research assessing causal effect: An official American Thoracic Society Research Statement. Am J Resp and Crit Care Med. 2020; 203(1): 14-23.

Learning Objectives:

  • Describe the American Thoracic Society (ATS) research statement on making healthcare decisions and establishing clinical practice guidelines and healthcare policies for critically ill patients based on findings from observational studies of the causal effect of an intervention on outcomes.
  • Develop recommendations for the use of findings from observational studies of the causal effect of an intervention on outcomes in establishing clinical practice guidelines and healthcare policies and making healthcare decisions for critically ill patients.

Abrams D, Montesi S, Moore SKL et al. Powering bias and clinically important treatment effects in randomized trials of critical illness. Crit Care Med. 2020; 48: 1710-1719.

Learning Objectives:

  • Describe the study by Abrams and colleagues of powering bias and clinically important treatment effects in multicenter randomized controlled trials (RCTs) of critically ill adults.
  • Develop recommendations for the design of multicenter randomized controlled trials (RCTs) of critically ill adults.

Module 1B: Infectious Diseases
ACPE Number: 0204-0000-22-933-H01-P

This module focuses on current issues in infectious diseases including updated guidelines, reviews, and clinical trials.  

Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridiodes difficile infection in adults. Clin Inf Dis. 2021; 73:e1029-e1044.

Learning Objectives:

  • Describe the clinical practice guideline with a 2021 focused update from the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) on the management of Clostridioides difficile infection (CDI) in adults.
  • Develop recommendations for the management of Clostridioides difficile infection (CDI) in adults based on the 2021 focused update from IDSA and SHEA.

Saag MS. HIV Infection - screening, diagnosis, and treatment. N Engl J Med. 2021; 384: 2131-2143.

Learning Objectives:

  • Describe the screening, diagnosis, and treatment of HIV infection.
  • Develop recommendations for the screening, diagnosis, and treatment of HIV infection.

Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis, 2021;72(7):1109-1116.

Learning Objectives:

  • Describe the Infectious Diseases Society of America (IDSA) guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa).
  • Develop recommendations for the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa).

Centers for Disease Control and Prevention. Sexually transmitted infectionis treatment guidelines, 2021. MMWR. 2021;70(4):1-192.
(IMPORTANT: For this Literature Study, only pages 65-80 (chlamydia and gonorrhea) are assessed.)

Learning Objectives:

  • Describe the 2021 Centers for Disease Control and Prevention (CDC) treatment guidelines for sexually transmitted infections involving Chlamydia trachomatis and Neisseria gonorrhoeae.
  • Develop recommendations for screening for and treating chlamydial and gonococcal infections.

Bernard L, Arvieux C, Brunschweiler B et al. Antibiotic therapy for 6 or 12 weeks fo rprosthetic joint infection. N Engl J Med. 2021; 384:1991-2001.

Learning Objectives:

  • Describe the Duration of Antibiotic Treatment in Prosthetic Joint Infection (DATIPO) study by Bernard and colleagues.
  • Develop recommendations for antibiotic therapy for patients with microbiologically confirmed prosthetic joint infections managed with standard surgical procedures.

Sutton JD, Steven VW, Chang NC et al. Oral β-lactam antibiotics vs fluoroquinolones or trimethoprim-sulfamethoxazole for definitive treatment of Enterobacterales bacteremia from a urine source. JAMA Netw Open. 2020; 3(10):e2020166.
(IMPORTANT: Information contained in the Supplement is also assessed.)

Learning Objectives:

  • Describe the study by Sutton and colleagues comparing oral β-lactam antibiotics with a fluoroquinolone or trimethoprim-sulfamethoxazole for the treatment of Enterobacterales bacteremia with a suspected urinary source.
  • Develop recommendations for the treatment of adults with Enterobacterales bacteremia with a suspected urinary source.

Module 1C: Pediatrics, Pain, and Neurology
ACPE Number: 0204-0000-22-934-H01-P

This module focuses on pediatrics, pain management, and the treatment and prevention of ischemic stroke.

Kelley-Quon LI, et al. Guidelines for opioid prescribing in children and adolescents after surgery: An expert panel opinion. JAMA Surg. 2021; 156: 76-90.

Learning Objectives:

  • Describe the guidelines from Kelley-Quon and colleagues for opioid prescribing in children and adolescents after surgery.
  • Develop recommendations for perioperative and postoperative opioid use in children and adolescents.

Brandow AM, Carroll CP, Creary S, Edwards-Elliott R, Glassberg J, Hurley RW, Kutlar A, Seisa M, Stinson J, Strouse JJ, Yusuf F, Zempsky W, Lang E. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv. (2020) 4 (12): 2656–2701.
https://doi.org/10.1182/bloodadvances.2020001851

Learning Objectives:

  • Describe the American Society of Hematology (ASH) 2020 guidelines for the management of acute and chronic pain in patients with sickle cell disease (SCD).
  • Develop recommendations for managing acute and chronic pain in patients with sickle cell disease (SCD).
  • Identify limitations to the current ASH guidelines and opportunities for future research.

Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021; 52: e364-e467.

Learning Objectives:

  • Describe the 2021 guideline from the American Heart Association (AHA) and American Stroke Association (ASA) for the secondary prevention of stroke in patients with stroke or transient ischemic attack (TIA).
  • Develop recommendations for the secondary prevention of stroke in patients with ischemic stroke or transient ischemic attack (TIA).

Herpich F, Rincon F. Management of Acute Ischemic Stroke. Crit Care Med. 2020; 48 (11): 1654-1663.

Learning Objectives:

  • Describe the management of acute ischemic stroke (AIS), including early detection, prehospital and emergency management, neuroimaging, revascularization, management in the intensive care unit (oxygen, ventilation, blood pressure, glucose, cerebral edema, fever), rehabilitation, nutrition, and secondary prevention through risk factor modification.
  • Develop recommendations for the management of acute ischemic stroke.

Zhong CS, Beharry J, Salazar D, et al. Routine use of tenecteplase for thrombolysis in acute ischemic stroke. Stroke 2021; 52: 1087-1090.

Learning Objectives:

  • Describe the study by Zhong and colleagues of tenecteplase for thrombolysis in patients with acute ischemic stroke.
  • Develop recommendations for thrombolytic therapy in patients with acute ischemic stroke.

Full Faculty Bios

Samuel L. Aitken, Pharm.D., M.P.H., BCIDP
Clinical Pharmacy Specialist - Infectious Diseases
The University of Texas MD Anderson Cancer Center
Houston, Texas 

Meagan Adamsick, Pharm.D., BCIDP
Clinical Pharmacy Specialist
Massachusetts General Hospital
Boston, Massachusetts 

Monique Bidell, Pharm.D., BCPS
Infectious Diseases Clinical Pharmacist
Massachusetts General Hospital
Boston, Massachusetts 

Dana R. Bowers, Pharm.D., BCIDP, BCPS (AQ-ID)
Clinical Assistant Professor
Washington State University
College of Pharmacy and Pharmaceutical Sciences
Yakima, Washington 

Christopher Carter, Pharm.D., BCCCP, FCCM
Clinical Manager - Pharmacy Services
SSM Health St. Clare Hospital – Fenton
Fenton, Missouri 

Brooklyn Cobb, Pharm.D., BCPS
Clinical Pharmacy Specialist, Ambulatory Care
Memorial Hermann Southwest Hospital
Houston, Texas 

Brian Dee, Pharm.D., BCCCP, BCNSP, FCCM
Clinical Pharmacy Specialist - Critical Care/Nutrition Support
The University of Texas MD Anderson Cancer Center
Houston, Texas 

Julie Harting, Pharm.D., BCIDP
Associate Professor / Clinical Pharmacist Specialist, Infectious Disease
Sullivan University College of Pharmacy and Health Sciences / University of Louisville Hospital
Louisville, Kentucky 

Lauren Igneri, Pharm.D., BCPS, BCCCP
Clinical Pharmacy Specialist, Critical Care
Cooper University HealthCare
Camden, New Jersey 

Bryan Lizza, Pharm.D., M.S., BCCCP
Clinical Specialist - Medicine Critical Care
Barnes Jewish Hospital
St Louis, Missouri 

Lindsay McCann, Pharm.D., BCCCP
Critical Care Clinical Pharmacy Specialist
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania 

Lane Nguyen, Pharm.D., BCPPS
Clinical Pharmacy Specialist
Pediatric Critical Care Medicine
Memorial Sloan Kettering Cancer Center
New York, New York 

Neha Sheth Pandit, Pharm.D., BCPS, AAHIVP
Associate Professor
University of Maryland
School of Pharmacy
Baltimore, Maryland 

Ashley Sabus, Pharm.D., BCOP
Clinical Pharmacy Specialist - Pediatric Oncology/Bone Marrow Transplant
Texas Children's Hospital
Houston, Texas 

Rachel Swope, Pharm.D., BCCCP
Clinical Pharmacy Manager
Norton Healthcare
Louisville, Kentucky 

Content Matter Experts

Christopher Betz, Pharm.D., BCPS, FASHP, FKSHP
Professor, Department of Clinical and Administrative Sciences
Sullivan University College of Pharmacy
Cardiology Clinical Pharmacy Specialist
Jewish Hospital Rudd Heart and Lung Center
Louisville, Kentucky 

Snehal Bhatt, Pharm.D., BCPS
Associate Professor of Pharmacy Practice
Massachusetts College of Pharmacy and Health Science
Clinical Pharmacist
Beth Israel Deaconess Medical Center
Boston, Massachusetts 

Angela Bingham, Pharm.D., BCPS, BCNSP, BCCCP, FASPEN, FCCP
Interim Vice Chair and Associate Professor of Clinical Pharmacy, PGY2 Critical Care Pharmacy Residency Program Director, Residency Programs Coordinator
Philadelphia College of Pharmacy, University of the Sciences
Philadelphia, Pennsylvania
Critical Care Clinical Pharmacy Specialist
Cooper University Hospital
Camden, New Jersey 

Kevin W. Garey, Pharm.D., M.S., FASHP, FIDSA
Professor and Chair
University of Houston
Houston, Texas 

Mary M. Hess, Pharm.D., FASHP, FCCM, FCCP, BCCCP
Associate Dean
Professor, Pharmacy Practice
Jefferson College of Pharmacy
Philadelphia, Pennsylvania 

Jason J. Schafer,Pharm.D., M.P.H., BCPS, BCIDP, AAHIVP, FASHP
Professor and Vice Chair, Department of Pharmacy Practice
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania 

Douglas Slain, Pharm.D., BCPS, AQ-ID
Professor & Infectious Diseases Clinical Specialist
West Virginia University
Morgantown, West Virginia 

Kayla R. Stover, Pharm.D., BCPS, BCIDP, FCCP, FIDSA
Associate Professor
University of Mississippi School of Pharmacy
Madison, Mississippi 

Paul M. Szumita, Pharm.D., BCCCP, BCPS, FASHP, FCCM
Director of Clinical Pharmacy
Brigham & Women's Hospital
Boston, Massachusetts 

Evan Zasowski, Pharm.D., M.P.H., BCPS, BCIDP
Assistant Professor, Department of Clinical Sciences
Touro University California College of Pharmacy
Vallejo, California

Susan R. Dombrowski, M.S., R.Ph.
Anna M. Wodlinger-Jackson, Pharm.D., BCPS

Jennifer Adema, Pharm.D., MBA, BCPS
Dawn Anderson, Pharm.D., MBA, BCPS
Angela Antoniello, Pharm.D., BCPS
John Austin, Pharm.D., BCPS, BCCCP
Carrie Baker, Pharm.D., MBA, BCPS
Mary Grace Bouldin, Pharm.D., BCPS
Quintin Broussard, Pharm.D., BCPS, BCCCP, BCNSP
Jennifer Catlin, Pharm.D, BCPS, BCCCP
Sara Davis, Pharm.D., BCPS
Shannon Eidsness, Pharm.D., BCPS
Michelle Fang, Pharm.D., BCPS
Stefanie Forman, Pharm.D., BCPS, BCCCP
Lauren Giblin, Pharm.D., BCPS
Carmen  Gust, Pharm.D., BCPS
Julie Haase, Pharm.D., BCPS, BCCCP
Brianne Hansen, Pharm.D., BCPS, BCCCP
Kiah Hicks, Pharm.D., BCPS
Laura Hicks, R.Ph., BCPS
Diem Ho, Pharm.D., BCPS
Raquel  Jones, Pharm.D., BCPS
Jacky Lee, Pharm.D., BCPS, BCCCP
Isaiah Liebel, Pharm.D., BCPS
Kimberley Limouze, Pharm.D., BCPS, BCCCP
Melanie Madorsky, Pharm.D., BCPS, BCCP, BCCCP
Claudia Martin Diaz, Pharm.D., BCPS, BCOP
Kathryn McCanna, Pharm.D., BCPS
Sarah Miller, Pharm.D., BCPS
Oussayma Moukhachen, Pharm.D., BCPS, BCCCP
Madeline Ott, Pharm.D., BCPS
Kalindi Patel, Pharm.D.,BCPS
Cara Phillips, Pharm.D., BCPS, BCCCP
Rebecca Powell, Pharm.D., BCPS
Kaitlin Pruskowski, Pharm.D., BCPS, BCCCP, FCCM
Hugh  Quinn, Pharm.D., BCPS
Katy Rolfes, Pharm.D., BCPS, BCCCP
Nahirony  Sanchez, Pharm.D., BCPS, BCGP
Nicholas Scarpino, Pharm.D., BCPS
Bridger Singer, Pharm.D., BCPS, BCCCP
Donald Singh, Pharm.D., MBA, BCPS
Katherine Taylor, Pharm.D., BCPS
Jonathan Tiongson, Pharm.D., BCPS
Jordan Todd, Pharm.D., BCPS
Emily Valentine, Pharm.D., BCPS
Barbara Wiggins, Pharm.D., BCPS, BCCP, BCCCP
Michael Wysong, Pharm.D., BCPS
Cathy Young, Pharm.D., BCPS, NCPS

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

The following persons in control of this activity’s content have relevant financial relationships:
     Snehal Bhatt: Speakers Bureau, Janssen Pharmaceuticals, Inc.

All other persons in control of content do not have any relevant financial relationships with an ineligible company.

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  •          Complete the attestation statement
  •          Review all content
  •          Complete and pass the assessments
  •          Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

These activities were developed by ASHP.